Evidence map›Paper›PMID 34934197›Full record

ReviewActa pharmacologica Sinica2022

GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.

Yan Chen, Ying-Na Xu, Chen-Yu Ye, Wen-Bo Feng, Qing-Tong Zhou, De-Hua Yang, Ming-Wei Wang

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmacologica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yan Chen *Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Ying-Na Xu *Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Chen-Yu Ye *Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Wen-Bo Feng *Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Qing-Tong ZhouDepartment of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
De-Hua YangThe CAS Key Laboratory of Receptor Research and The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. dhyang@simm.ac.cn.
Ming-Wei WangDepartment of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. mwwang@simm.ac.cn.
Fudan University · CNShanghai Institute of Materia Medica · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonalcoholic steatohepatitis (NASH), as a severe form of nonalcoholic fatty liver disease (NAFLD), is characterized by liver steatosis, inflammation, hepatocellular injury and different degrees of fibrosis. The pathogenesis of NASH is complex and multifactorial, obesity and type 2 diabetes mellitus (T2DM) have been implicated as major risk factors. Glucagon-like peptide-1 receptor (GLP-1R) is one of the most successful drug targets of T2DM and obesity, and its peptidic ligands have been proposed as potential therapeutic agents for NASH. In this article we provide an overview of the pathophysiology and management of NASH, with a special focus on the pharmacological effects and possible mechanisms of GLP-1 mimetics in treating NAFLD/NASH, including dual and triple agonists at GLP-1R, glucose-dependent insulinotropic polypeptide receptor or glucagon receptor.

Indexed as

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsObesityGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHypoglycemic Agentsdual agonistsGLP-1 mimeticsGLP-1RGPCRNAFLDNASHtriple agonists

Identifiers

PMID34934197
PMCPMC9061743
OpenAlexW4200470685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.